Clinical use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in Gulf Cooperation Council Countries - EVOLVE

Study identifier:D8851R00001

ClinicalTrials.gov identifier:NCT05315323

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

Clinical Use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting – A Multi-center Observational Prospective Study to Determine Utilization and Clinical Outcomes of EVUSHELD in Gulf Cooperation Council Countries

Medical condition

COVID-19

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

550

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 23 Jun 2022
Estimated Primary Completion Date: 30 Jun 2024
Estimated Study Completion Date: 30 Jun 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria